AAAAAA
Results:
1-14
|
Results: 14
Authors:
CRAIG C
RACE E
SHELDON J
WHITTAKER L
GILBERT S
MOFFATT A
ROSE J
DISSANAYEKE S
CHIRN GW
DUNCAN IB
CAMMACK N
Citation: C. Craig et al., HIV PROTEASE GENOTYPE AND VIRAL SENSITIVITY TO HIV PROTEASE INHIBITORS FOLLOWING SAQUINAVIR THERAPY, AIDS, 12(13), 1998, pp. 1611-1618
Authors:
RACE E
GILBERT SM
SHELDON JG
ROSE JSL
MOFFATT AR
SITBON G
DISSANAYEKE SR
CAMMACK N
DUNCAN IB
Citation: E. Race et al., CORRELATION OF RESPONSE TO TREATMENT AND HIV GENOTYPIC CHANGES DURINGPHASE-III TRIALS WITH SAQUINAVIR AND REVERSE-TRANSCRIPTASE INHIBITOR COMBINATION THERAPY, AIDS, 12(12), 1998, pp. 1465-1474
Authors:
HARE DL
PHILLIPS PA
RACE E
FITZGERALD H
Citation: Dl. Hare et al., RANDOMIZED STUDY OF RISK FACTOR MAINTENANCE STRATEGIES AFTER EARLY REHABILITATION, Circulation, 96(8), 1997, pp. 1062-1062
Authors:
GOBLE A
JACKSON B
PHILLIPS P
RACE E
OLIVER RG
WORCESTER MC
Citation: A. Goble et al., THE FAMILY ATHEROSCLEROSIS RISK INTERVENTION STUDY (FARIS) - RISK FACTOR PROFILES OF PATIENTS AND THEIR RELATIVES FOLLOWING AN ACUTE CARDIAC EVENT, Australian and New Zealand Journal of Medicine, 27(5), 1997, pp. 568-577
Authors:
WIGG MD
ALJABRI AA
COSTA SS
RACE E
BODO B
OXFORD JS
Citation: Md. Wigg et al., IN-VITRO VIRUCIDAL AND VIRUSTATIC ANTI HIV-1 EFFECTS OF EXTRACTS FROMPERSEA-AMERICANA MILL (AVOCADO) LEAVES, Antiviral chemistry & chemotherapy, 7(4), 1996, pp. 179-183
Authors:
CRAIG C
RACE E
SHELDON J
WHITTAKER L
TOMLINSON PW
MOFFAT A
GILBERT S
DUNCAN IB
ROBERTS NA
Citation: C. Craig et al., SAQUINAVIR (SQV) DOES NOT SELECT FOR UNIVERSAL CORESISTANCE WITH OTHER PROTEINASE-INHIBITORS (PI) IN PATIENTS, AIDS, 10, 1996, pp. 13-13
Authors:
GILBERT SM
JUPP R
MOFFATT AR
SHELDON JG
RACE E
Citation: Sm. Gilbert et al., IN-VITRO SELECTION OF HIV-1 VARIANTS WITH REDUCED SENSITIVITY TO SAQUINAVIR AND RITONAVIR BY SUCCESSIVE SEQUENTIAL PASSAGE, AIDS, 10, 1996, pp. 14-14
Authors:
RACE E
GILBERT SM
SHELDON JG
MOFFAT AR
TOMLINSON PW
DUNCAN IB
Citation: E. Race et al., LOW OCCURRENCE OF REDUCED SENSITIVITY TO SAQUINAVIR IN ANTIVIRAL COMBINATION - RESULTS FROM A PHASE-III CLINICAL-TRIAL (NV-14256), AIDS, 10, 1996, pp. 15-15
Authors:
RACE E
GILBERT SM
SHELDON JG
MOFFAT AR
TOMLINSON PW
DUNCAN IB
Citation: E. Race et al., AN OVERVIEW OF DRUG-RESISTANCE DURING SAQUINAVIR TREATMENT, AIDS, 10, 1996, pp. 25-25
Authors:
RACE E
STEIN CA
WIGG MD
BAKSH A
ADDAWE M
FREZZA P
OXFORD JS
Citation: E. Race et al., A MULTISTEP PROCEDURE FOR THE CHEMICAL INACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS FOR USE AS AN EXPERIMENTAL VACCINE, Vaccine, 13(16), 1995, pp. 1567-1575
Authors:
RACE E
FREZZA P
STEPHENS DM
DAVIS D
POLYANSKAYA N
CRANAGE M
OXFORD JS
Citation: E. Race et al., AN EXPERIMENTAL CHEMICALLY INACTIVATED HIV-1 VACCINE INDUCES ANTIBODIES THAT NEUTRALIZE HOMOLOGOUS AND HETEROLOGOUS VIRUSES, Vaccine, 13(1), 1995, pp. 54-60
Authors:
OXFORD JS
ZUCKERMAN MA
RACE E
DOURMASHKIN R
BROADHURST K
SUTTON PM
Citation: Js. Oxford et al., SODIUM DEOXYCHOLATE EXERTS A DIRECT DESTRUCTIVE EFFECT ON HIV AND INFLUENZA-VIRUSES IN-VITRO AND INHIBITS RETROVIRUS-INDUCED PATHOLOGY IN AN ANIMAL-MODEL, Antiviral chemistry & chemotherapy, 5(3), 1994, pp. 176-181
Authors:
HARRICH D
HSU C
RACE E
GAYNOR RB
Citation: D. Harrich et al., DIFFERENTIAL GROWTH-KINETICS ARE EXHIBITED BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAR MUTANTS, Journal of virology, 68(9), 1994, pp. 5899-5910
Authors:
OXFORD JS
FREZZA P
RACE E
Citation: Js. Oxford et al., CHALLENGES AND STRATEGIES FOR AIDS VACCINE DEVELOPMENT, Vaccine, 11(6), 1993, pp. 612-614
Risultati:
1-14
|